58 completed, 19 terminated, 10 unknown, 6 recruiting. 33 Phase 3, 21 Phase 2, 19 Phase 4, 11 Not applicable, 4 Phase 1.
Follow Dalteparin: new trials by email Literature Review of Dalteparin trials Research Report on Dalteparin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival LMW Heparin 5000 U/ML-Aspirin 75 MG, LMW Heparin 5000 U/ML - Complication,Postoperative | Not applicable | Unknown | Aga Khan University | 126 | 2025-01-01 | 2024-07-23 |
| A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery Low Molecular Weight Heparin (dalteparin) - Colorectal Surgery, VTE (Venous Thromboembolism) | Not applicable | Not yet recruiting | Beijing Friendship Hospital | 1448 | 2024-10-01 | 2024-09-04 |
| RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Rivaroxaban 10 MG, Low Heparin Molecular Weight - Venous Thromboembolism, Deep Vein Thrombosis | Phase 3 | Recruiting | University Hospital, Angers | 1424 | 2024-07-19 | 2026-06-25 |
| Prolonged Hypercoagulability Following Major Liver Resection for Malignancy Redesca (enoxaparin sodium for injection), Fragmin (dalteparin) - Hepatic Disease, Surgery-Complications | Phase 3 | Not yet recruiting | Western University, Canada | 50 | 2024-06-01 | 2024-04-23 |
| THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) Dalteparin Sodium, Tinzaparin Sodium, Enoxaparin Sodium - Venous Thromboembolism, Varicose Veins | Phase 4 | Recruiting | Imperial College London | 3175 | 2024-01-22 | 2026-06-04 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis Enoxaparin, Dalteparin, Tinzaparin - Cancer-associated Thrombosis, Thrombocytopenia | Phase 4 | Recruiting | Tzu-Fei Wang | 50 | 2022-08-29 | 2025-12-17 |
| Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism Tissue Plasminogen Activator, Alteplase, Low-molecular weight heparin - Pulmonary Embolism | Unknown | Ege University | 100 | 2022-06-03 | 2022-09-01 | |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| Pre- Vs Postoperative Thromboprophylaxis for Liver Resection enoxaparin or tinzaparin or dalteparin, No intervention - Liver Cancer, Surgery | Phase 4 | Recruiting | Helsinki University Central Hospital | 1012 | 2021-02-10 | 2025-02-14 |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE theraputic heparin, prophylactic heparin, P2Y12 - Covid19 | Phase 4 | Completed | Matthew Neal MD | 3591 | 2020-09-04 | 2024-12-30 |
| Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (Arm Closed) Nafamostat Mesilate, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin - SARS-CoV-2 Infection (COVID-19) | Phase 3 | Unknown | University of Melbourne | 2200 | 2020-07-28 | 2024-05-16 |
| Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 Enoxaparin - COVID, Thrombosis | Phase 4 | Completed | Central Hospital, Nancy, France | 1000 | 2020-05-13 | 2023-08-07 |
| Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin - Sars-CoV2, COVID | Phase 3 | Completed | Northwell Health | 257 | 2020-04-26 | 2021-11-22 |
| Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients Dose of Tinzaparin or Dalteparin - Covid-19, Thromboembolic Events | Completed | Karolinska Institutet | 166 | 2020-03-06 | 2020-06-22 | |
| Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients Dose of tinzaparin or dalteparin - Covid19, Thromboembolism | Completed | Karolinska Institutet | 257 | 2020-03-01 | 2023-05-31 | |
| Immunosuppressant Regimens for Living Fetuses Study Prednisone, Hydroxychloroquine, Aspirin - Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss | Not applicable | Unknown | RenJi Hospital | 420 | 2019-08-02 | 2019-08-12 |
| A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement Dimolegin 40 mg, Dimolegin 60 mg, Fragmin - Venous Thromboembolism | Phase 2 | Unknown | PharmaDiall Ltd. | 240 | 2019-05-31 | 2022-05-02 |
Showing 20 of 96. Sign in to see all of them.
Venous Thromboembolism (29) · Venous Thrombosis (25) · Pulmonary Embolism (20) · Thrombosis (12) · Thromboembolism (11) · Neoplasms (10) · Hemorrhage (6) · COVID-19 (5) · Thrombophilia (5) · Critical Illness (4) · Lung Neoplasms (4) · Pancreatic Neoplasms (4) · Multiple Myeloma (3) · Renal Insufficiency (3) · Atrial Fibrillation (2)
Pfizer (11) · Ottawa Hospital Research Institute (5) · McMaster University (4) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (3) · M.D. Anderson Cancer Center (3) · Duke University (2) · Hamilton Health Sciences Corporation (2) · Karolinska Institutet (2) · Ontario Clinical Oncology Group (OCOG) (2) · Sanofi (2) · Sunnybrook Health Sciences Centre (2) · University of Oklahoma (2) · University of Southern California (2) · Academic and Community Cancer Research United (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
Canada (36) · United States (35) · Italy (13) · United Kingdom (11) · France (10) · Netherlands (10) · Spain (10) · Austria (8) · Germany (8) · Norway (8) · Belgium (7) · Denmark (7) · Australia (6) · Sweden (6) · Poland (5)
Deborah J Cook, MD (3) · Jim Julian, MMath (2) · Leslie Skeith, MD (2) · Marc Carrier, MD (2) · Marc Rodger, MD (2) · Mark Levine, MD (2) · Michael J Kovacs, MD, FRCPC (2) · Agnes Lee, MD (1) · Alex C Spyropoulos, MD (1) · Ann Mohrbacher, MD (1) · Anthony Maraveyas (1) · Anton Skaro, MD PhD (1) · Benedicte Gaborit (1)
PMID 33337539, PMID 33779986, PMID 33502773, PMID 34172290, PMID 17855670, PMID 19348685, PMID 32358837, PMID 35244208, PMID 10648016, PMID 12090565, PMID 16310609, PMID 16716321, PMID 17075810, PMID 1757934, PMID 17882417, PMID 18315876, PMID 18667193, PMID 18779469, PMID 19327956, PMID 19390908, PMID 19807917, PMID 20447951, PMID 20528832, PMID 21417952, PMID 21482348, PMID 22100906, PMID 22244711, PMID 22360152, PMID 22449204, PMID 22476844, PMID 22635227, PMID 23089679, PMID 23659733, PMID 23788287, PMID 23871290, PMID 23942857, PMID 24125514, PMID 24638843, PMID 24726205, PMID 24768093, PMID 24807875, PMID 24818590, PMID 24917564, PMID 25066248, PMID 25280034, PMID 25305214, PMID 25373438, PMID 25528663, PMID 25900749, PMID 25903529
1OT2HL156812-01 (1), 2014 (1), 2016 (1), 2023 (1), R01HL095109 (1), U01HL086755 (1), U01HL087229 (1)